Latest Endothelix News
Aug 11, 2023
Global Endothelial Dysfunction: Competitive Landscape and Key Developments ZOLL Medical Corp, Sphingo Tec GmbH, Lawrence Berkeley National Laboratory, The Polymath Co, Endothelix Inc, Perimed AB, SMART Medical Ltd, Everist Health Inc, Alam Medical SaRl, and Medizinische Messtechnik GmbH among others are a few of the key companies operating in the endothelial dysfunction market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their endothelial dysfunction market share. A few of the recent developments in the global endothelial dysfunction market are mentioned below: In April 2023, Perimed signed an agreement with Lovell Government Services. Lovell’s customers are Federal, State, and Local Governments such as the Department of Veteran Affairs (VA), Defense Logistics Agency, and Department of Defense in the United States. With this agreement, Perimed gains an additional sales channel as Lovell will notify the company of any government contract opportunities within its field of business and bid on Perimed’s behalf. In April 2021, Berkeley Lab developed flow-mediated dilation device to monitor both endothelial function and endothelium-independent vasodilation. In 2021, Medizinische Messtechnik GmbH launched VasoScreen 1000. It is used for arterial vascular diagnosis on arms, legs, or the head. Browse key market insights spread across 198 pages with 113 list of tables & 80 list of figures from the report, "Endothelial Dysfunction Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Cause (Hypertension, Diabetes, Hypercholestrolaemia, Bechet’s Disease, Obesity, and Others), Test Type [Invasive Tests and Non-Invasive Tests (Flow Mediated Dilatory, Peripheral Arterial Tonometry (PAT), Venous Occlusion Pletismography, Circulating Markers, and Others)], and End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics, and Others)" in detail along with the table of contents: https://www.theinsightpartners.com/reports/endothelial-dysfunction-market Rising Incidences of High Cholesterol, Diabetes, And Obesity to Drive Global Endothelial Dysfunction Market Growth During 2022-2028: Lifestyle changes lead to a rise in the incidences of diabetes, hypertension, dyslipidemia, and obesity, increasing the chances of endothelial dysfunction. However, these can be prevented through proactive monitoring, early diagnosis, and physical activity. Metabolic syndrome is a group of disorders that increases the risk of CAD, diabetes, high blood pressure, and other serious health problems. According to an article on "Metabolic syndrome," published in the National Heart, Lung, and Blood Institute (NHLBI), metabolic diseases are widespread in the US. i.e., one in three adults suffers from metabolic syndrome. Type 2 diabetes is already a major public health problem and is increasingly rising among the children and young adults associated with obesity. According to the World Health Organization (WHO), diabetes was the direct cause of 1.5 million deaths in 2019, and 48% of all deaths from diabetes occurred before age 70. Another 460,000 deaths from kidney disease were caused by diabetes. Elevated blood sugar causes ~20% of cardiovascular deaths. According to the CDC, diabetes was the eighth leading cause of death in the US in 2020. Adults aged 50 years and older suffering from diabetes die 4.6 years earlier, develop disability 6–7 years earlier, and spend nearly 1–2 years or longer in a disabled state than adults without diabetes, causing diabetes endothelial dysfunction. According to the WHO, ~38.2 million children under five were overweight or obese in 2019 worldwide. Of them, almost half were in Asia. Overweight and obesity, once considered a problem in high-income countries, is now increasing in low- and middle-income countries, particularly in urban areas. Hypertension is the leading cause of endothelial dysfunction and cardiovascular disease leading to premature death worldwide. The number of adults aged 30–79 with hypertension has increased from 650 million to 1.28 billion over the past 30 years, according to the first comprehensive global analysis of trends in the prevalence, detection, treatment, and control of hypertension among the population, headed by Imperial College London and WHO. In addition, according to the World Heart Federation, high cholesterol causes 4.4 million deaths annually. It is a major risk factor for heart disease and stroke in both high- and low-income countries. According to the WHO, high cholesterol caused an estimated 2.6 million deaths in 2022. High cholesterol is one of the major contributors to disease burden in developed and developing countries and a risk factor for heart disease. Increased consumption of high-fat and high-sugar foods and physical immobility due to inactivity in different types of work, changing modes of transportation, and increasing urbanization all contribute to the growth of diseases such as diabetes, obesity, cholesterol, and high blood pressure. Therefore, the growing prevalence of such diseases is boosting the endothelial dysfunction market growth. Directly Purchase this Report at https://www.theinsightpartners.com/buy/TIPRE00011290 Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount): Hypertension Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis Hypercholesterolemia Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur
Endothelix Frequently Asked Questions (FAQ)
When was Endothelix founded?
Endothelix was founded in 2003.
Where is Endothelix's headquarters?
Endothelix's headquarters is located at 8275 El Rio, Houston.
What is Endothelix's latest funding round?
Endothelix's latest funding round is Spinoff / Spinout.
Who are the investors of Endothelix?
Investors of Endothelix include University of Texas Health Science Center at Houston and Houston Angel Network.
Who are Endothelix's competitors?
Competitors of Endothelix include Endotronix, SonarMed, Symetis, VytronUS, Vascular Pathways and 7 more.
Compare Endothelix to Competitors
ExploraMed is a medical technology incubation company dedicated to the identification, creation and development of medical device solutions. ExploraMed creates ideas in the fields of clinical, engineering, legal, strategic marketing, and financing, while focusing on efficient and timely development.
Global Blood Resources is a company that is making advances in whole blood recovery, salvaging, and transfusions.Their main product is the Hemobag which is a device that returns a patient's own blood to their body during invasive surgery. This product is an alternative to risky transfusions.
GRAFTcath is a medical device company developing vascular access products for hemodialysis.
Endotronix develops an integrated platform to provide reimbursable health management tools for patients suffering from chronic heart failure. The company's solution includes a cloud-based disease management data system and outpatient hemodynamic management with a wireless pulmonary artery sensor for early detection of worsening heart failure.
Tayside Flow Technologies Limited is a medical device company. It had developed the Spiral Laminar Flow Vascular Arteriovenous Graft.Tayside Flow Technologies Ltd (TFT) is a medical technology company focussed on the development of cardiovascular devices based on a new understanding of blood flow dynamics, Spiral Laminar Flow.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.